secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evommune, Inc. (EVMN)
CIK:        0002044725
Form:       8-K
Filed at:   2026-09-23T20:05:30+00:00
Accession:  0001193125-26-399378
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evommune to present Phase 2a EVO301 AD data at EADV 2026; Phase 2b planned mid-2027
--------------------------------------------------------------------------------

- Phase 2a EVO301 (IL-18 binding protein) atopic dermatitis data in late-breaker Oct 1 at EADV Vienna; presenter Dr. Mark G. Lebwohl.
- Topline results previously reported this year; Phase 2b dose-ranging study in moderate-to-severe AD expected to start mid-2027.
- EVO301 targets IL-18 upstream of Th2 axis, modulating Th1, Th2, Th17/22 and innate inflammatory pathways.
- CEO Luis Peña cites 29M patients in 7 major markets needing advanced AD therapy; IL-18 offers broad-spectrum potential.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2044725/000119312526399378/0001193125-26-399378-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2044725/000119312526399378/evmn-20260923.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-399378

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer